SciBase: Interim report

0
98

 

The second quarter in figures

  • Net sales amounted to TSEK 2,258 (1,683).
  • The loss after tax amounted to TSEK 11,151 (8,864).
  • The loss per share amounted to SEK 0.19 (0.38).
  • The cash flow from current operations was negative in the amount of TSEK 9,162 (8,704).
  • The gross margin reached 56.3% (55.7%).
  • Electrode sales volume increased by 28% and reached 5,968 (4,672) units. Repeat sales of electrodes to existing customers increased by 23%.

January – June in figures

  • Net sales amounted to TSEK 4,821 (4,179).
  • The loss after tax amounted to TSEK 19,304 (17,800).
  • The loss per share amounted to SEK 0.34 (0.89).
  • The cash flow from current operations was negative in the amount of TSEK 18,635 (16,597).
  • The gross margin reached 54.4% (54.7%).
  • Electrode sales volume increased by 19% and reached 13,464 (11,270) units. Repeat sales of electrodes to existing customers increased by 20%.

Important events during the quarter

  • Overall sales increased by 34% (cleared for currency effects +43%). Covid-19 continues to affect sales and the market situation remains difficult to predict going forward, due to ongoing lockdowns and reduced marketing activities. Sales in the company’s key market Germany increased by 13% (cleared for currency effects +19%).
  • SciBase performed two successful directed share issues which raised approximately MSEK 66.5 net, after issue costs.
  • SciBase submitted the first US reimbursement application to CMS’s Medicare Contractor in Florida, First Coast Service Options (FCSO). The application for Medicare coverage in Florida marks an important step in the reimbursement process for SciBase and is a necessary step towards broader penetration and usage of the Nevisense test.
  • SciBase received certification under the new Medical Device Regulation (MDR).
  • The new Non-Melanoma Skin Cancer (NMSC) clinical application was launched following the completion of the MDR certification process.
  • A groundbreaking article by key SciBase collaborator Professor Cezmi Akdis presenting the “epithelial barrier hypothesis” was published in Nature Reviews Immunology. The article presented the background for the steep increase in allergic and other diseases over the last decades, and how this increase is connected to degradation in barrier function in the body.
  • A new clinical study from the Swiss Institute of Allergy and Asthma Research (SIAF) was published in the European Journal of Allergy and Clinical Immunology (Allergy). In the study Nevisense was used to assess the skin barrier of patients with atopic dermatitis (AD) and could accurately detect signs of barrier degradation in atopic patients, even in visually unaffected skin. Nevisense measurements also correlated with relevant biomarkers for atopic dermatitis.
  • The notice to attend the AGM 2021 was published as well as the nominating committees supplementary proposal to nominate Dr Matt Leavitt for the Board of Directors.
  • The AGM 2021 was held on May 18.
  • An EGM was held on June 16th.
  • The annual report 2020 was published on April 9th.

Important events after the end of the  period

  • SciBase has entered into an agreement with Vator Securities AB (“Vator Securities“) regarding the service as a Certified Adviser. Vator Securities will take over as Certified Adviser on September 28, 2021. Until Vator Securities takes over, Avanza Bank AB will continue to act as Certified Adviser for the Company.

Apr 1 – June 30

Jan 1 – June 30

July 1 2020 –
June 30 2021

Jan 1 – Dec 31

THE GROUP

2021

2020

2021

2020

Rolling-12

2020

Net sales, SEK ths

2 258

1 683

4 821

4 179

10 163

9 521

Gross margin, %

56,3%

55,7%

54,4%

54,7%

52,5%

52,5%

Equity/Asset ratio, %

87,3%

69,2%

87,3%

69,2%

81,7%

79,1%

Net indebtness, multiple

0,15

0,44

0,15

0,44

0,22

0,26

Cash equivalents, SEK ths

88 192

30 450

88 192

30 450

88 192

41 427

Cashflow from operating activities, SEK ths

-9 162

-8 704

-18 635

-16 597

-35 899

-33 861

Earnings per share (before and after dilution), SEK

-0,19

-0,38

-0,34

-0,89

-0,72

-1,12

Shareholder’s equity per share, SEK

1,59

1,44

1,65

1,68

1,25

1,50

Average number of shares, 000′

59 265

23 265

57 023

19 942

50 949

31 287

Number of shares at closing of period, 000′

68 236

36 560

68 236

36 560

68 236

54 780

Share price at end of period, SEK

5,52

2,44

5,52

2,44

5,52

4,62

Number of sold electrodes, pieces

5 968

4 672

13 464

11 270

27 880

25 686

Average number of employees

17

16

17

16

17

16


This information is information that SciBase Holding AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out below, at 08.00 CET on August 19, 2021.

This information is information that SciBase Holding AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out below, at 08.00 CET on August 19, 2021.

LEAVE A REPLY

Please enter your comment!
Please enter your name here